Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.10
MDVN's Cash to Debt is ranked higher than
57% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. MDVN: 1.10 )
MDVN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.1

Equity to Asset 0.20
MDVN's Equity to Asset is ranked higher than
51% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MDVN: 0.20 )
MDVN' s 10-Year Equity to Asset Range
Min: 0.01   Max: 0.99
Current: 0.2

0.01
0.99
F-Score: 1
Z-Score: 7.76
M-Score: -0.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -8.15
MDVN's Operating margin (%) is ranked higher than
78% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. MDVN: -8.15 )
MDVN' s 10-Year Operating margin (%) Range
Min: -510.27   Max: 66.67
Current: -8.15

-510.27
66.67
Net-margin (%) -15.61
MDVN's Net-margin (%) is ranked higher than
76% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. MDVN: -15.61 )
MDVN' s 10-Year Net-margin (%) Range
Min: -496.58   Max: 37.65
Current: -15.61

-496.58
37.65
ROE (%) -55.38
MDVN's ROE (%) is ranked higher than
60% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. MDVN: -55.38 )
MDVN' s 10-Year ROE (%) Range
Min: -2940.27   Max: 4.99
Current: -55.38

-2940.27
4.99
ROA (%) -10.85
MDVN's ROA (%) is ranked higher than
75% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. MDVN: -10.85 )
MDVN' s 10-Year ROA (%) Range
Min: -73.93   Max: 4.69
Current: -10.85

-73.93
4.69
ROC (Joel Greenblatt) (%) -47.79
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. MDVN: -47.79 )
MDVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -230657.14   Max: -47.79
Current: -47.79

-230657.14
-47.79
Revenue Growth (%) 58.60
MDVN's Revenue Growth (%) is ranked higher than
97% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. MDVN: 58.60 )
MDVN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 60
Current: 58.6

0
60
EBITDA Growth (%) -19.00
MDVN's EBITDA Growth (%) is ranked higher than
66% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. MDVN: -19.00 )
MDVN' s 10-Year EBITDA Growth (%) Range
Min: -22.5   Max: 154.6
Current: -19

-22.5
154.6
EPS Growth (%) 4.50
MDVN's EPS Growth (%) is ranked higher than
84% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. MDVN: 4.50 )
MDVN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 71
Current: 4.5

0
71
» MDVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

MDVN Guru Trades in Q1 2013

Steven Cohen 565,217 sh (+63.95%)
Louis Moore Bacon 150,000 sh (+50%)
RS Investment Management Sold Out
Andreas Halvorsen 904,500 sh (-73.04%)
» More
Q2 2013

MDVN Guru Trades in Q2 2013

Andreas Halvorsen 1,685,216 sh (+86.31%)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
» More
Q3 2013

MDVN Guru Trades in Q3 2013

Steven Cohen 1,900 sh (New)
Andreas Halvorsen Sold Out
» More
Q4 2013

MDVN Guru Trades in Q4 2013

Jim Simons 94,000 sh (New)
Steven Cohen 6,888 sh (+262.53%)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-03-31 Sold Out 0.1%$45.84 - $75.56 $ 57.93-4%0
George Soros 2011-12-31 New Buy0.1%$15.79 - $48.8 $ 57.9373%50000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Medivation, Inc.

Weekly CEO Sells Highlight: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc and HomeAway Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Vringo Inc, Medivation Inc, BioDelivery Sciences International Inc, and HomeAway Inc. Read more...

Ratios

vs
industry
vs
history
P/B 56.90
MDVN's P/B is ranked lower than
77% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. MDVN: 56.90 )
MDVN' s 10-Year P/B Range
Min: 0.59   Max: 1848.25
Current: 56.9

0.59
1848.25
P/S 15.95
MDVN's P/S is ranked lower than
58% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. MDVN: 15.95 )
MDVN' s 10-Year P/S Range
Min: 4.54   Max: 563.33
Current: 15.95

4.54
563.33
EV-to-EBIT 17.20
MDVN's EV-to-EBIT is ranked higher than
62% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. MDVN: 17.20 )
MDVN' s 10-Year EV-to-EBIT Range
Min: 52.4   Max: 10203.9
Current: 17.2

52.4
10203.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 56.80
MDVN's Price/Tangible Book is ranked lower than
91% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. MDVN: 56.80 )
MDVN' s 10-Year Price/Tangible Book Range
Min: 0.37   Max: 1152.75
Current: 56.8

0.37
1152.75
Price/Median PS Value 0.50
MDVN's Price/Median PS Value is ranked higher than
88% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. MDVN: 0.50 )
MDVN' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 1.43
Current: 0.5

0.26
1.43
Forward Rate of Return (Yacktman) 11.13
MDVN's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. MDVN: 11.13 )
MDVN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 99.1   Max: 146.6
Current: 11.13

99.1
146.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:WMD.Germany
Medivation, Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI (enzalutamide) capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics, Inc., or MPT, Medivation Neurology, Inc., or MNI, Medivation Technologies, Inc., or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which previously was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration, or FDA, for the post-docetaxel indication. The Company has obtained an exclusive, worldwide commercial license to a series of novel small molecules. The Company is conducting this program in collaboration with Astellas. Its business strategy is to use current GMP compliant contract manufacturers for manufacture of clinical supplies as well as for commercial supplies if required by its commercialization plans, and to transfer manufacturing responsibility to its collaboration partners when possible. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide